Vascular Medicine最新文献

Identifying predictors of durable treatment response among patients with claudication: A secondary analysis of the CLEVER trial. 确定跛行患者持久治疗反应的预测因素：对CLEVER试验的二次分析。

IF 3 3区医学

Vascular Medicine Pub Date : 2025-05-26 DOI: 10.1177/1358863X251333932

Firas Hentati, Brett J Carroll, Timothy P Murphy, Madeleine R Murphy, Eric A Secemsky

{"title":"Identifying predictors of durable treatment response among patients with claudication: A secondary analysis of the CLEVER trial.","authors":"Firas Hentati, Brett J Carroll, Timothy P Murphy, Madeleine R Murphy, Eric A Secemsky","doi":"10.1177/1358863X251333932","DOIUrl":"https://doi.org/10.1177/1358863X251333932","url":null,"abstract":"Background: Symptomatic peripheral artery disease (PAD) is prevalent and guideline-recommended therapies include optimal medical therapy (OMT), supervised exercise therapy (SET), and revascularization (stenting). The Claudication: Exercise Versus Endoluminal Revascularization (CLEVER) trial examined longitudinal patient-reported outcomes to assess response to OMT, SET, and stenting. The predictors of symptomatic improvement have not been fully assessed.Methods: This is a secondary analysis of the CLEVER trial, which randomized patients with claudication to OMT alone, OMT plus SET, or OMT plus stenting. The primary outcome was a change in the Peripheral Artery Questionnaire (PAQ) summary score by 10 points or more from baseline to 6 and 18 months. Multivariate logistic regression was used to identify predictors of response.Results: Of the 103 participants (66 men, median age 63 years), 65 (63%) had a response to therapy at 6 months. Of 98 participants who completed the 18-month PAQ, 52 (53%) had a symptomatic response. On binary logistic regression, when compared to OMT, SET (6 months: odds ratio [OR] 4.25, 95% CI: 1.33-13.58; 18 months: OR 3.92, 95% CI: 1.04-14.70) and ST (6 months: OR 5.19, 95% CI: 1.58-17.03; 18 months: OR 11.50, 95% CI: 2.89-45.72) were associated with an increase in PAQ at 6 and 18 months.Conclusion: Among randomized patients in the CLEVER trial, treatment with either SET or stenting was predictive of clinically meaningful change in the PAQ summary score from baseline to 6 and 18 months. These interventions, with a prioritization of SET, should be more widely available to patients with PAD. This study adds to the findings of the CLEVER trial by denoting that SET and stenting are beneficial in patients with PAD, independent of comorbidities.","PeriodicalId":23604,"journal":{"name":"Vascular Medicine","volume":" ","pages":"1358863X251333932"},"PeriodicalIF":3.0,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144151956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Vascular Medicine Patient Information Page: What is a vascular medicine specialist? 血管医学患者信息页面：什么是血管医学专家？

IF 3 3区医学

Vascular Medicine Pub Date : 2025-05-26 DOI: 10.1177/1358863X251343051

Devanshi N Damani, Joshua A Beckman, Bruce Gray, Naomi M Hamburg, Michael S Levy, Heather L Gornik

引用次数: 0

Endovascular renal denervation for the treatment of hypertension. 血管内肾去神经支配治疗高血压。

IF 3 3区医学

Vascular Medicine Pub Date : 2025-05-23 DOI: 10.1177/1358863X251322179

Duc M Giao, Alex M Poluha, Eric A Secemsky, Anna K Krawisz

{"title":"Endovascular renal denervation for the treatment of hypertension.","authors":"Duc M Giao, Alex M Poluha, Eric A Secemsky, Anna K Krawisz","doi":"10.1177/1358863X251322179","DOIUrl":"https://doi.org/10.1177/1358863X251322179","url":null,"abstract":"Endovascular renal denervation (RDN) is a catheter-based, procedural therapy for the treatment of hypertension that was approved by the US Food and Drug Administration (FDA) in November 2023. Early studies suggest that endovascular RDN reduces blood pressure (BP) in patients with hypertension. However, BP response to RDN is highly variable, optimal patient selection remains uncertain, and the procedure's high cost remains a significant challenge. The purpose of this review is to comprehensively examine the literature regarding the mechanism by which endovascular RDN reduces BP and the safety and effectiveness of RDN, and to discuss key considerations for selecting appropriate patients for endovascular RDN. Relevant studies in the field were identified from PubMed using search terms including 'renal denervation' and 'renal denervation for hypertension.' In conclusion, clinical trials have demonstrated a statistically significant BP-lowering effect of endovascular RDN, which based on multiple trials with long-term follow-up, appears to persist over several years with low complication rates. More research is needed to understand which patients benefit most from endovascular RDN and to evaluate the long-term outcomes, including the impact of endovascular RDN on cardiovascular events.","PeriodicalId":23604,"journal":{"name":"Vascular Medicine","volume":" ","pages":"1358863X251322179"},"PeriodicalIF":3.0,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144128789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association of cognitive impairment and peripheral artery disease (PAD): A systematic review. 认知障碍与外周动脉疾病（PAD）的关联：一项系统综述。

IF 3 3区医学

Vascular Medicine Pub Date : 2025-05-21 DOI: 10.1177/1358863X251336736

Beth L Cheshire, Sarah J Messeder, Coral J Pepper, Lucy C Beishon, Rob D Sayers, John Sm Houghton

{"title":"Association of cognitive impairment and peripheral artery disease (PAD): A systematic review.","authors":"Beth L Cheshire, Sarah J Messeder, Coral J Pepper, Lucy C Beishon, Rob D Sayers, John Sm Houghton","doi":"10.1177/1358863X251336736","DOIUrl":"https://doi.org/10.1177/1358863X251336736","url":null,"abstract":"This systematic review aimed to describe the association between peripheral artery disease (PAD) and cognitive impairment or dementia. We included studies reporting on the association between PAD (defined by ankle-brachial index ⩽ 0.9) and cognitive function in adult populations. MEDLINE, Embase, CINAHL, PsycINFO, and CENTRAL were systematically searched from inception to January 2025. Study quality was assessed using the Risk of Bias In Nonrandomized Studies of Exposure effects (ROBINS-E) tool. A narrative synthesis was undertaken structured by cognitive outcome and study design. Thirty-eight studies were included in the review (58,586 participants). The results provide evidence that PAD is associated with cognitive impairment. Seventeen (81%) cross-sectional studies and four (67%) longitudinal studies reported associations of PAD with poorer cognitive performance or increased risk of cognitive impairment. Impaired memory and processing speed were most frequently associated with PAD. PAD was also associated with increased dementia risk in cross-sectional (odds ratios = 1.50-2.41) and longitudinal studies (hazard ratios = 1.03-2.40), although proportionally fewer longitudinal studies reported significant association of PAD with dementia. Results suggest increased prevalence of cognitive impairment, independent of cardiovascular risk factors and cerebrovascular disease. Awareness of the prevalence of cognitive impairment and its potential impact on treatment adherence and engagement in a healthy lifestyle is important for clinicians treating patients with PAD. Screening for cognitive impairment in those with PAD may aid early diagnosis and management of cognitive impairment in this high-risk population. Further research is required to determine whether screening for and optimal management of PAD has cognitive benefits. (PROSPERO Registration No.: CRD42023399608).","PeriodicalId":23604,"journal":{"name":"Vascular Medicine","volume":" ","pages":"1358863X251336736"},"PeriodicalIF":3.0,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144112086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Associations between neck circumference, obstructive sleep apnea, and arterial stiffness in older adults. 老年人颈围、阻塞性睡眠呼吸暂停和动脉僵硬之间的关系。

IF 3 3区医学

Vascular Medicine Pub Date : 2025-05-20 DOI: 10.1177/1358863X251334144

Oscar H Del Brutto, Robertino M Mera, Aldo F Costa, Denisse A Rumbea, Emilio E Arias, Pablo R Castillo, Victor J Del Brutto

引用次数: 0

Images in Vascular Medicine: Hybrid surgical repair of a giant Kommerell diverticulum in a bovine aortic arch. 血管医学影像：牛主动脉弓内巨大Kommerell憩室的混合手术修复。

IF 3 3区医学

Vascular Medicine Pub Date : 2025-05-20 DOI: 10.1177/1358863X251333622

Elisabetta Tanda, Giuseppe Deiana, Francesco Spanu, Genadi Genadiev, Mario Moro, Roberta Arzedi, Giovanni Ruiu, Stefano Camparini

引用次数: 0

Disease-specific knowledge among veterans with peripheral artery disease. 外周动脉疾病退伍军人的疾病特异性知识。